Celldex Therapeutics Inc (CLDX) FinancialsCLDXCelldex Therapeutics Inc

Evaluating the bottom line, Celldex Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -366468.18%, while the net margin is -334104.55%. These profitability ratios, combined with a Return on Equity (ROE) of -43.88%, provide a clear picture of how effectively CLDX converts its operational activities into shareholder value.

In the context of the broader market, CLDX competes directly with industry leaders such as RXRX and ADMA. With a market capitalization of $2.56B, it holds a leading position in the sector. When comparing efficiency, CLDX's gross margin of 100.00% stands against RXRX's -49.82% and ADMA's 69.31%. Such benchmarking helps identify whether Celldex Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Celldex has reported a gross margin of 100% across recent quarters, indicating strong potential for profitability if revenue increases. However, net income remains negative, with a reported loss of $78.685 million in Q1 2026.